drugset / Trial / NCT05906511

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

NCT05906511

RandomizedCrossoverDouble-blindOther

Summary

The overarching goal of this double-blind, placebo-controlled, crossover study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) effects of the main analgesic and psychoactive constituent of cannabis, delta-9 tetrahydrocannabinol (THC), among older adults - the fastest growing population of cannabis consumers, and the most likely age cohort to use cannabinoids to relieve pain. This protocol includes two sub-studies, each randomizing 20 men and women aged 65 years or older to receive two administration routes of THC; oral administration and vaporized administration.

Timeline

Start
2023-10-17
Primary completion
2026-04-13
Completion
2026-08-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dronabinol Other / unclassified 5 mg Oral
Comparator Dronabinol Other / unclassified 10 mg Oral
Comparator delta-9-tetrahydrocannabinol Other / unclassified 2 mg Other
Comparator delta-9-tetrahydrocannabinol Other / unclassified 4 mg Other

Indications